This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
MarketOptimizer.org adds OpportunityAnalyzer Graft-Versus-Host Disease Opportunity Analysis and Forecasts to 2018 to its store. The GVHD market was valued at $297.0m across the 6MM in 2013, and is expected to increase to $409.0m in 2018.
Dallas, Texas (PRWEB) August 22, 2014
The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%. The companys latest report OpportunityAnalyzer Graft-Versus-Host Disease Opportunity Analysis and Forecasts to 2018 states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period.
Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&Js Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that are efficient in GVHD with GI involvement. Gaining more and more ground in the treatment management of cGVHD is Roches Rituxan that estimates will be one of the bestselling biologics in GVHD in the US by 2018.
The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.
Analyst covering Immunology says: Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblasts first-to-market Prochymal expected to generate sales of $12.2 million in 2018. Analyst forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively.
Key Questions Answered
Order a purchase copy at http://www.marketoptimizer.org/contacts/purchase?rname=9780.
(This is a premium report priced at US$5995 for a single user License)
List of Companies
Inquire before buying at http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=9780. (This is a premium report priced at US$5995 for a single user License.)
Reasons to Buy
Explore more reports on Energy industry at http://www.marketoptimizer.org/category/energy-power/energy.
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
For the original version on PRWeb visit: http://www.prweb.com/releases/graft-versus-host-disease/market-outlook-to-2018/prweb12111757.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.